Glioblastoma-Initiating Cells: Relationship with Neural Stem Cells and the Micro-Environment by Goffart, Nicolas & KROONEN, Jérôme






Glioblastoma-Initiating Cells: Relationship with Neural Stem 
Cells and the Micro-Environment 
Nicolas Goffart 1,†, Jérôme Kroonen 2,3,† and Bernard Rogister 1,4,5,* 
1 Laboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center,  
University of Liège, Liège 4000, Belgium; E-Mail: ngoffart@student.ulg.ac.be 
2 Human Genetics, CHU and University of Liège, Liège 4000, Belgium;  
E-Mail: Jerome.kroonen@chu.ulg.ac.be 
3 The T&P Bohnenn Laboratory for Neuro-Oncology, Department of Neurology and Neurosurgery, 
UMC Utrecht, Utrecht 3556, The Netherlands; E-Mail: J.B.G.Kroonen-2@umcutrecht.nl 
4 Department of Neurology, CHU and University of Liège, Liège 4000, Belgium 
5 GIGA-Development, Stem Cells and Regenerative Medicine, University of Liège, Liège 4000, Belgium 
† These authors contributed equally to this work. 
* Author to whom correspondence should be addressed; E-Mail: Bernard.Register@ulg.ac.be;  
Tel.: +32-4-366-5950; Fax: +32-4-366-5912. 
Received: 26 June 2013; in revised form: 29 July 2013 / Accepted: 1 August 2013 /  
Published: 14 August 2013 
 
Abstract: Glioblastoma multiforme (GBM, WHO grade IV) is the most common and lethal 
subtype of primary brain tumor with a median overall survival of 15 months from the time of 
diagnosis. The presence in GBM of a cancer population displaying neural stem cell (NSC) 
properties as well as tumor-initiating abilities and resistance to current therapies suggests that 
these glioblastoma-initiating cells (GICs) play a central role in tumor development and are 
closely related to NSCs. However, it is nowadays still unclear whether GICs derive from 
NSCs, neural progenitor cells or differentiated cells such as astrocytes or oligodendrocytes. On 
the other hand, NSCs are located in specific regions of the adult brain called neurogenic niches 
that have been shown to control critical stem cell properties, to nourish NSCs and to support 
their self-renewal. This “seed-and-soil” relationship has also been adapted to cancer stem cell 
research as GICs also require a specific micro-environment to maintain their “stem cell” 
properties. In this review, we will discuss the controversies surrounding the origin and the 
identification of GBM stem cells and highlight the micro-environment impact on their biology. 
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Malignant gliomas represent some of the greatest challenges in the management of cancer patients 
worldwide. Primary brain tumors are indeed considered amongst the most refractory malignancies and 
their most aggressive form, glioblastoma multiform (GBM, WHO grade IV), is also the most common 
and lethal subtype [1]. Although notable recent achievements have been made in oncology, using  
state-of-the-art neuroimaging techniques for surgical resections along with multimodal radio- and 
chemotherapy, the patients’ median survival hardly reaches 15 months from the time of diagnosis [2,3]. 
This catastrophic survival rate mainly is the consequence of systematic relapses which reflect the 
failure of the current therapeutic strategies. 
Over the last decade, a large number of different treatments were tested but displayed very limited 
efficacy. One of the most difficult problems in GBM multimodal therapy is to target the largest 
number of tumor cells. In this context, surgery often is ineffective given the invasive nature of the 
tumor, making the entire surgical resection of the tumor mass quite impossible without causing harm to 
the healthy brain. Moreover, particular regions of the brain are hardly amenable to surgical intervention 
(basal ganglia, brain stem) which makes the prognosis of the disease even worse. On the other hand, 
chemotherapeutic strategies are associated with several limitations as well. Various factors such as the 
size of the molecule, the lipophilicity of the drug, the presence of active efflux pumps and the integrity of 
the blood-brain barrier influence the access of the drug to the brain parenchyma and the tumor itself [4]. 
Recent studies have indeed demonstrated that the most forceful agents in glioma therapy achieve 
relatively low concentrations in the tumor surroundings due to the inability of the drug to cross the 
blood-brain barrier [5,6]. Finally, recent integrated genomic analysis shed the light on the tumor inter- and 
intra-heterogeneity. Indeed, The Cancer Genome Atlas (TCGA) classifies GBM based on PDGFRA, 
IDH1, EGFR and NF1 abnormalities in classical, mesenchymal, pro-neural and neural subtypes [7]. 
Moreover, all of these subtypes could be found in distinct areas of a single tumor as well [8]. The lack of 
treatment efficacy could therefore be found in this complex intra- and/or inter-tumor genetic heterogeneity. 
For years, parallelisms have been made between stem cell biology and oncology, notably because of 
the growing evidence that genes with important roles in stem cell biology also play a role in cancer. As 
a result, the concept of a cancer stem cell population (CSCs) was hypothesized; concept in which a 
relatively small percentage of cells would share characteristics with normal stem cells and display 
features including maintained proliferation, self-renewal and differentiation abilities. Nowadays, the 
existence of such fraction of cells, referred to as cancer stem cells or tumor-initiating cells has been 
described in many tumors [9] including brain cancers [10–12] and raised a new hope in order to 
understand why glioblastomas so systematically relapse. Further down the road, glioblastoma stem 
cells, or initiating cells (GICs), were notably shown to be involved in experimental tumorigenesis, 
tumor maintenance and therapeutic resistance [13–16]. Moreover, this sub-population of cells with 
tumor-initiating abilities also display neural stem cell (NSC) properties which suggests that NSCs 




could play a major role in tumor development and sheds the light on the kinship between GICs and 
NSCs [12]. However, the basic nature of GICs is nowadays still unclear, whether they derive from 
NSCs, neural progenitor cells or differentiated cells such as astrocytes or oligodendrocytes. On the 
other hand, NSCs are located in specific regions of the brain called neurogenic niches which retain the 
ability to produce neurons and glia throughout life, functioning as a source of stem cells and progenitors 
in adults [17,18]. Those niches are essential to control critical stem cell properties, to feed the NSCs and 
to support their self-renewal abilities. This “seed-and-soil” relationship has also been adapted to GBM 
stem cell research, as GICs also seem to require specific interactions with the micro-environment in 
order to maintain their stem-like properties and their ability to drive tumor growth [19]. Prospective 
identification and targeting of GICs is thus mandatory in order to fully understand their own biology, 
to prevent GBM relapses and to develop new powerful therapeutic strategies. In this review, we will 
debate over the controversies surrounding the origin and the identification of GICs and discuss the 
impact of the micro-environment on the biology of GICs. 
2. GBM Origin(s) 
The cells responsible for the onset of malignant gliomas have been source of dissension for many 
years and are still under intense investigation, whether they could be astrocytes, glial precursors, or 
stem cells (Figure 1) [20]. In a manner consistent with the stem cell theory, growing evidences aim to 
demonstrate that only a limited amount of cells, exhibiting stem cell-like properties in the primary 
tumor, are able to trigger cancer initiation [20,21]. On the other hand, periventricular adult NSCs 
express high levels of glial fibrillary acidic protein (GFAP) which raised exciting questions on whether 
or not astrocytes could be involved in GBM initiation. Following those observations, two major 
hypotheses have been put forward: the astrocytes dedifferentiation theory and the glioblastoma stem 
cell theory. 
2.1. The Dedifferentiation Theory 
In this hypothetical view, tumorigenesis is regarded as a multi-step process accompanied with 
genetic alterations which lead to the progressive transformation of normal cells into highly malignant 
cells. In this case, six major alterations are required for cancer progression: self-sufficiency in growth 
signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed cell death 
(apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis [22]. 
In this context, it has recently been demonstrated that the activation of specific oncogenes concomitant 
with the loss of tumor suppressors in cortical astrocytes trigger cancer initiation with histological 
features similar to GBM [12]. As an example, the loss of INK4A/Arf associated with the activation of 
K-Ras and Akt in mature astrocytes lead to the formation of tumors closely related to GBM 
morphology. In this model, loss of INK4A/Arf induces the dedifferentiation of astrocytes which 
consequently become more sensitive to malignant transformation via activated oncogenes such as  
K-Ras [23]. At the same moment, another study strengthened the idea that astrocytes might be at the 
origin of malignant astrocytomas. Indeed, the combined loss of tumor suppressors p16(INK4a) and 
p19(ARF) enabled astrocytes to dedifferentiate in response to EGFR activation. Transduction of 
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inhibition of tumor suppressor Ink4a/Arf in nestine-positive progenitor cells but not in GFAP positive 
progenitors [29]. 
2.2. The Stem Cells Theory 
Rudolf Virchow has described this second theory for the first time in 1863. Based on histological 
similarities between embryonic stem cells and cancer cells, Virchow proposed that tumors originally 
develop from “dormant” or quiescent cells located in the host tissue. From then on, the existence of such 
a fraction of cells has been described in many types of cancers [9] including brain tumors [10–12]. As a 
matter of fact, astrocytic gliomas contain a sub-population of cells which exhibits stem cell-like 
properties such as multipotentiality, the ability to self-renew or to form neurospheres in vitro [30–32]. 
Interestingly, growth properties of glioma-derived neurospheres in vitro were found to be significant 
predictors of tumor progression and clinical outcome [33]. 
In the same line, several genetic studies using murine glioma models and imaging analyses from 
clinical studies provided the evidence that GBM may arise from the SVZ stem cell niche (SVZ) [34–36]. 
This region notably maintains the ability to produce neurons and glia throughout life, functioning as a 
source of stem cells and progenitors in adults [17,18]. At this level, NSCs are hierarchically organized. 
Quiescent type B cells give rise to highly proliferative cells, also known as transit-amplifying progenitor 
cells (type C cells), which then differentiate into two lineage-restricted progenitor cells; neuroblasts 
(type A cells) and oligodendrocyte precursor cells (OPCs) [37,38]. In this context, tumor-initiating 
cells are thought to arise from quiescent type B cells located in the SVZ. Indeed, those cells were 
demonstrated to pile up the largest number of genetic mutations in a transgenic hGFAP-Cre/p53flox/flox 
mouse model. Conversely, this study also showed that transit amplifying type C cells were able to 
accumulate strings of alterations which finally lead to tumor initiation and that Olig2-positive type C 
cells were notably involved in the early stages of gliomagenesis [39]. Additionally, another study 
recently showed that intraventricular infusion of PDGF was able to induce PDGFR alpha-positive type 
B cells to proliferate, contributing in this way to the generation of large hyperplasias exhibiting some 
GBM features [40]. In parallel, various studies have demonstrated the presence of human cytomegalovirus 
(HCMV) in GBM. This virus is now accepted as a tumor promoter in malignant brain tumor [41]. It 
has also been shown that HCMV preferentially infects NSCs. In this context, it has been hypothesized that 
NSCs’ modulation by HCMV may contribute to the brain tumor genesis [42]. However, there are no 
reports so far on how HCMV modulates the pre-tumorigenic environment of the brain.  
Although the SVZ is usually considered to be the stem cell compartment for glioma formation in 
mice following the introduction of genetic alterations observed in adult malignant brain tumors [34,39,43], 
several other germinal zones in the brain could potentially be at the origin of brain tumorigenesis as 
well, including the third and the fourth ventricle [44,45]. For instance, it has been shown that pediatric 
gliomas are more likely to arise from NSCs located in the third ventricle [46]. This observation notably 
allowed us to shed the light on the crucial role of innate brain region NSCs’ heterogeneity in the 
patterning of gliomagenesis both in children and adults.  
In 2009, the first example of a donor-derived brain tumor was reported. A boy with ataxia 
telangiectasia was treated with intracerebellar injection of human NSCs and was then diagnosed with a 
multifocal brain tumor four years after the treatment. Molecular and cytogenetic studies revealed that the 




tumor was derived from at least two donors, suggesting in this case the implication of NSCs in 
gliomagenesis [47]. This work was the first report of a human brain tumor complicating neural stem 
cell therapy but has also been nuanced by other studies which, nevertheless, do not minimize the role 
of stem-cell-like astrocytes during reactive neurogenesis after brain injury or disease and during brain 
tumorigenesis [48].  
Finally, a very important study recently underlined the crucial role of NSCs in brain tumors and the 
relevance of initial genetic mutations in the pathogenesis. While recombination of PTEN/p53 in NSCs 
gave rise to gliomas, the deletion of either Rb/p53 or Rb/p53/PTEN generated primitive neuroectodermal 
tumors (PNET), indicating the significant role of the initial Rb loss in driving the PNET phenotype [43]. 
Futhermore p53, Rb and RTK were shown to be core-signaling pathways commonly activated in GBM [49]. 
2.3. The Midway Theory 
However, despite the plethora of examples showing that both astrocytes and NSCs seem to be 
strong contenders involved in malignant brain tumor formation, the GBM cell of origin remains largely 
elusive. Recent studies have indeed shown that other non-stem cells, including NG2+ cells [50] and 
oligodendrocyte precursors (OPCs) [51–53], can also be viewed as potential cells for the origin of 
malignant glioma [54]. As a matter of fact, OPCs are the most dividing cells in the adult brain. 
Whether this means those progenitors are more susceptible to tumorigenicity enhancement is yet to be 
determined. However, their proliferative ability and their broad distribution in the white matter as well 
as the grey matter make those cells potential suspects in gliomagenesis. Favorable indications 
supporting this hypothesis can be found in the literature. OPCs are plastic cells that can be converted  
in vitro to immature multipotent cells able to give rise to neurons, astrocytes and oligodendrocytes [55]. 
Glioblastomas freely express NG2 and PDGFR, two markers closely associated with OPCs [56]. 
Moreover, PDGFRα signaling pathway, controlling proliferation and migration of OPCs, is commonly 
altered in GBM [7,49,57]. 
Very recently, mosaic analysis with double markers confirmed that malignant transformation generating 
GBM only occurred in OPCs in a mouse model where NSCs are homozygously mutated for p53 and 
NF1 [51]. Interestingly, the authors also reported for the first time that the GBM “cell of origin” could 
be distinct from the cell of mutation. It is therefore of major interest to find reliable candidate in order to 
promote quiescence and differentiation of OPCs. As a first recent example, treatment of primary murine 
GBM cells with agonists of Grp17 resulted in a decreased number of neurospheres [58]. Grp17 is a 7TM 
receptor involved in the differentiation of OPCs which can be activated by two classes of molecules 
such as uracil-nucleotides and cysteinyl-leukotrienes [59]. 
Following this controversy, it is thus of great importance to gather major attention on the GIC 
population in order to better understand their biology and origin(s) (Figure 1) to improve or develop 
new groundbreaking therapeutic strategies. The induction of GICs’ differentiation into less proliferative 
cells [60] along with the inhibition of signaling pathways involved in GICs’ proliferation [61] or even 
the disruption of the GICs’ relationship with their micro-environment [19] are as many hints which are 
given for further investigations. 
  




3. The Tumor Micro-Environment 
Glioblastomas are made of heterogeneous cell populations which do not only catch external signals 
from the environment but also respond to the latter in order to take advantage of it. It is commonly 
accepted that tumor-associated parenchymal cells such as vascular cells, microglia, peripheral immune 
cells and neural precursor cells directly interact with GBM cells and play a crucial role in controlling 
the course of the pathology. In the following paragraphs, we will try to describe the multiple interactions 
between the GIC population and the parenchymal cells in order to highlight the pathological impact of 
the tumor micro-environment on malignant brain tumors (Figure 2). 
3.1. Involvement of Microglia 
Tumor-associated macrophages are the most predominant inflammatory cell type which infiltrate 
GBM [62] and account for the major non transformed cell population in GBM biopsies [63,64]. 
Tumor-associated microglia notably break into the tumor mass in response to chemo-attractive cytokines 
released by the tumor it-self such as monocyte chemotactic protein-3 (MCP-3), colony-stimulating 
factor 1 (CSF-1) and granulocyte-colony stimulatory factor (G-CSF) [65,66]. Malignant brain tumors 
take advantage of this situation since tumor-associated macrophages were shown to infiltrate the tumor 
in order to enhance GBM cells’ invasion by degrading the extracellular matrix. Indeed, microglia is 
able to trigger the release of membrane Type 1 metalloprotease (MT1-MMP) in response to soluble 
factors secreted by GBM cells which, in turn, release matrix metalloprotease 2 (MMP-2) that will be 
fully activated by the microglia MT1-MMP [67]. Matrix metalloprotease 2 is notably upregulated in 
microglia following the activation of the CX3CL1/CX3CR1 signaling pathway. Interestingly, 
chemokine receptor CX3CR1 was also shown to be upregulated in glioma associated microglia [68]. 
Moreover, a recent study showed that the common CX3CR1 allelic variant, termed V249I, was 
associated with increased GBM survival and reduced microglial cell infiltration in primary tumor 
biopsies as well [69]. All these findings definitely demonstrated the importance of microglia in GBM 
invasive properties and the necessity for developing more reliable in vivo models. We are convinced 
that better in vivo models would definitely improve our knowledge on those invasive tumor (initiating) 
cells which escape neurosurgery and radiotherapy modalities by leaving the tumor bulk. 
3.2. Involvement of the Immune System 
Following the example of tumor-associated macrophages, lymphocytes were also reported to 
infiltrate human gliomas. It has recently been suggested that a specific subtype of lymphocytes, 
regulatory T cells or Tregs, play an important role in the regulation of the immune response. In 2007, 
El Andaloussi and Lesniak described a positive correlation between the progression of the disease and 
the presence of Tregs in tumors with high malignancy [70]. Once again, chemokines such as CCL2 
and CCL22 were incriminated for the attraction of Tregs towards the tumor site [71]. This specific 
infiltration was correlated with an increase in TGF-β1 mRNA and protein expression in a model of 
intracranial xenografts. The crucial role of the brain environment was markedly put to light in this study 
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3.3. Involvement of Neural Progenitors 
Throughout the last decade evidence is accumulating that glioblastomas also interact with neural 
progenitor cells (NPCs) in the micro-environment. It has indeed been widely demonstrated that 
endogenous NPCs, from the subventricular zone or from the corpus callosum, preferentially home to 
experimentally induced brain tumors [73–76] probably in a CXCR4 dependent-manner [77]. Those 
tumor-associated NPCs are in fact diverted from their physiological migratory path in order to end up 
their journey in cellular layers surrounding the tumor mass [76]. There, they display important 
antitumorigenic effects by releasing soluble factors which interfere with GBM cell proliferation [78,79], 
causing GBM cell death [76] and promoting GICs’ differentiation [73]. Moreover, significant survival 
improvements were observed in vivo using orthotopic coinjection of NPCs together with glioblastoma 
cells. This study also demonstrated that the tumor-suppressor effect of NPCs is largely related to aging 
and neurogenic abilities since younger mice significantly outlived older ones. Strikingly, this survival 
default was sealed by inoculating GBM cells along with NPCs in older mice brains suggesting the close 
relationship between NPCs’ antitumorigenic properties and neurogenic aptitudes [76]. Let’s keep in 
mind that the antitumorigenic capacity of NPCs has only been described in rodent models. It seems 
therefore required to check if human NPCs also display antitumorigenic properties similar to what has 
been described in rodents so far, especially since aging is considered as one of the most important 
prognostic factor for the disease. Moreover, the fact that neurogenesis declines with aging in humans [80] 
strengthens the link between GBM and this prognostic factor even more, notably by potentially 
decreasing the amount of NPCs and their related antitumorigenic effects throughout lifespan. 
3.4. Involvement of the Vascular Niche 
In physiological context, NSCs are located in specific regions of the brain called neurogenic  
niches [81,82]. Those niches, usually defined by a large vasculature network, have been the center of 
attention for many years since these anatomical structures were demonstrated to be the stem cell niches for 
normal and malignant neural tissue as well. Indeed, just like the adult NSCs, GICs also rely on vascular 
niches in order to control the balance between self renewal capacities and differentiation [19,83,84]. 
Moreover, let’s just not forget that high grades glioma are mainly characterized by hallmarks such as 
endothelial hyperplasia and microvascular proliferation which are associated with a transition to a 
more aggressive phenotype, making  malignant gliomas among the most vascularized tumors [85]. 
The vascular niches have been shown to be the primary location for cancer cells with stem cell-like 
characteristics [86]. In parallel, it has recently been shown that GICs can acquire a specific endothelial 
phenotype in order to create an early bound between the vasculature network and the tumor mass [87]. 
Moreover, GICs preferentially associate with endothelial cells which, in turn, accelerate their tumorigenic 
capacities. In fact, endothelial cells were shown to selectively interact with the GIC population in culture 
and supply them with secreted factors which maintain these cells in a self-renewing and undifferentiated 
state. Moreover, increasing the number of endothelial cells or blood vessels in orthotopic brain tumor 
xenografts expanded the pool of self-renewing cancer stem cells and accelerated the initiation and 
growth of tumors [19]. Interestingly, protein ligands that are found within the vascular niche have been 
demonstrated to regulate both stem cell self-renewal and angiogenesis, putting forward the idea that 




these two processes are related. For instance, KIT ligand, also known to be a stem cell factor, was 
shown to be a powerful GBM-derived proangiogenic factor also involved in migration, survival and 
proliferation of NPCs [88,89]. In parallel, pigment epithelium-derived factor (PEDF) has also been 
demonstrated to play a crucial role in angiogenesis and to be involved in NSC self-renewal [90,91]. 
More recently, SVZ blood vessels and the ependymal cell layer of the vascular niche were shown to 
secrete CXCL12, creating in this way a u-shaped gradient in the niche [92]. Besides, chemokine 
receptor CXCR4 is known to be preferentially expressed by GICs [93] as well as the entire SVZ 
lineage [92]. In this study, the authors notably speculated that high levels of CXCL12 in the 
ependymal layer could help to promote quiescence. Indeed, high levels of CXCL12 were shown to 
result in receptor internalization, desensitization, and quiescence of hematopoietic stem cells, whereas 
lower concentrations resulted in proliferation and differentiation [94]. 
Following these observations, it has been suggested that the molecular crosstalk between GICs and 
the vascular network of the niches plays a critical role in tumor progression. A better understanding of 
these lines of communication will definitely provide new insights to improve the actual therapeutic 
means and develop new therapies which better target the micro-environment. 
As a clinical example, there are considerable paracrine interactions between endothelial cells and 
the brain tumor cells in the micro-environment notably through the release of endothelial-derived soluble 
factors such as VEGF [95]. This factor has been shown to mediate the intercellular crosstalk between 
GICs and the tumor endothelium in order to induce angiogenesis [96]. Interestingly, neo-angiogenesis 
in astrocytomas reflects the tumor grade and is therefore often correlated with the poor prognosis or 
the aggressive phenotype of the disease. Furthermore, the increased amount of VEGF in the tumor 
micro-environment has been demonstrated to enhance the ability of GICs to promote angiogenesis 
compared to the non tumor-initiating cell populations [96,97]. Although the molecular mechanisms 
underlying this increase of VEGF production remain unclear, environmental factors such as hypoxia or 
acidosis have been proposed to play an important role in this process [98,99]. Activation of oncogenes 
such as EGFR or loss of PTEN can also lead to higher levels of VEGF in malignant gliomas [100]. As 
a result, the use of bevacizumab, an anti-VEGF antibody, allowed to significantly reduce tumor 
angiogenesis both in vitro and in vivo [101]. It is possible that this drug directly disrupts the 
maintenance of GICs and, in this way, effectively eliminates the roots of tumor progression. Although 
data on randomized phase III clinical trials with anti-angiogenic molecules are not yet available, this 
treatment regimen is already applied in several clinical centers at the time of recurrence 
(NCT00671970 and NCT00350727, [102]). Our opinion is that future anti-angiogenic therapies will 
have to rely on strategies combining chemotherapy and drugs which target invasive GBM cells. 
Indeed, those cells, sometimes located far away from the highly vascularized tumor core, are notably 
not targeted by anti-angiogenic therapies. 
4. The Human SVZ and Its Clinical Implications in GBM 
The discovery by Eriksson et al., in 1998, of neural progenitor cells (NPCs) capable of becoming 
mature neurons in the human brain, thought for decades to be a quiescent organ, has brought the 
brain’s plasticity into sharp focus [103]. However, researches about stem cells implication in neurological 
disorder repair have met little success so far and their capacity to regenerate neurons after a lesion is, 




for now on, very limited. Indeed, NPCs were only found to replace interneurons in specific regions of 
the brain such as the olfactory bulbs or the dentatus gyrus. Human NPCs, which look like glial cells but 
with stem cell features, remain in the adult brain in two restricted regions after that the hippocampal 
sulcus has become the subgranular zone (SGZ) of the hippocampus and the lateral ganglionic 
eminences turned into the SVZ [104,105]. Because neurogenesis in the SGZ is rigidly fixed by the age 
of 30 and is composed of a very small number of cells and nor could a link be established between the 
hippocampus and brain tumors, we will only focus on the SVZ environment in this review. As a matter 
of fact, the SVZ is the region that borders the ependymal layer on the lateral wall of the lateral 
ventricle and is separated from the caudate nucleus by a layer of myelin [106]. In the late 90s, specific 
culture conditions, using neurosphere formation, were used in order to isolate cells from the lateral 
wall of the temporal lobe in epileptic patients. These experiments already suggested at that time the 
presence of human NSCs in the adult brain [107–109]. As shown in rodent, progenitor cells located in 
this specific area are able to produce neuroblasts which migrate and integrate the olfactory bulbs. 
However, it seems that there is a considerably less activity in the human SVZ compared to rodents. 
Nevertheless, those human progenitors have the ability to proliferate and migrate towards injured regions 
close to the SVZ. This should be taken into consideration for the development of new treatment in 
neurological disorders and for our basic understanding of GBM (Figure 3). 
The adult human SVZ hosts three types of cell harboring progenitor properties (A, B and C) as 
already mentioned in the previous section [110]. Type C cells are found in the deepest layer (regarding 
the ventricle’s wall) close to the myelin compartment. Type B cells are located in a well-defined cell-rich 
region. Type A cells staid in the cell-poor layer immediately beneath the ependymal layer. The ratio of 
cell types between rodent and human differs with the particularity that type A cells, or the migrating 
neuroblasts, are the most abundant in rodents while type B cells, identified as the most quiescent 
primary progenitors in rodents, are the major type in human [111,112]. Type C cells were shown to be 
less numerous in both species. 
In rodents, the migration of type A cells to the olfactory bulb to replace interneurons is well 
established [113–115]. Recently, Curtis and collaborators have extended this knowledge to humans 
and discovered that human neuroblasts are also able to leave the SVZ and reach the olfactory bulbs 
trough the rostral migratory stream (RMS), a vestigial lumen that connects the lateral ventricle to the 
olfactory bulb [116,117]. The human RMS harbor neurogenic properties with a large number of cells 
proliferating found on the road to the olfactory bulbs [118,119]. 
To date, many studies in rodents have currently supported the idea that the “cell of originin” 
malignant brain tumors could derive from SVZ progenitors. Unfortunately the biology and the precise 
contribution of neural progenitors to normal human brain functions remain to be addressed and the 
understanding of their roles in neurological diseases has just started. Beyond the hypothetic role of the 
SVZ in generating GBM, it could be that GICs do not originate from NPCs. Using bio-mathematical 
models, Bohnam and collaborators discovered that 50% of GBM are actually located away from the 
SVZ environment and that their SVZ origin would therefore be doubtful [120]. No matter what this 
study shows, let’s not forget that the SVZ offers a specific environment for GICs, as described in the 
previous section, which could directly or indirectly be involved in GBM growth and help to escape 
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The SVZ involvement has been assessed as a potential independent prognostic factor for the overall 
survival (OS) and the progression free survival (PFS) in GBM patients [121–124]. Radiological 
observations of an intimate contact with the SVZ demonstrated an association with poor survival rates. 
An interesting study reported a significant decrease of survival in patients bearing tumors connected to 
the lateral ventricle [122]. However, the observed median survival difference (8 vs. 11 months) did not 
show statistical signification after that patients had undergone surgery (11 vs. 14 months). In a same 
line, SVZ connexion profile, analyzed in a cohort of 47 GBM patients, failed to demonstrate a 
significant correlation with survival [121]. However, a trend to a shorter survival rate was once again 
observed when GBM cells invaded the SVZ environment (median OS of 358 vs. 644 months). Recently, 
Kaplan-Meier analyses on a cohort of 91 GBM patients demonstrated shorter PFS at 6 months (47% vs. 
69% survivors) as well as shorter OS at 2 years (23% vs. 48% survivors) in the group of patients 
whose tumors were connected to the SVZ compared with patients harboring no SVZ lesions [124]. 
This study also explored the impact of a cortical involvement and reported that such a relation does not 
exist. Nevertheless, conclusions reached by independent studies differ widely and the precise meaning 
of this phenotype is not clear yet. Cohort homogeneity may have contributed to this controversy. 
Tumor sizes were shown to be different between tumors classified according to the SVZ contact [125] 
but tumor volume did not impact survival [126]. However, the type of surgery performed, temolozomide 
adjuvant chemotherapy protocol and Karnofsky performance status score (KPS) are well-established 
independent prognostic factors of the disease [127–129]. Be that as it may, but the human SVZ has to 
be taken into consideration speaking about GBM.  
Radiotherapeutic data also support the claim that GBM are related to the SVZ. A group from the 
University of California Los Angeles (UCLA) tested the hypothesis that targeting adult neurogenic 
niches could be of benefit for GBM patients in a retrospective study of 55 patients, including 17 
patients with grade III and 38 patients with grade IV histology [130]. Aside the small size of the study 
and the lack of crucial information, the authors reported that a >43Gy irradiation dose of the ipsi- and 
contralateral SVZ increased the median progression free survival (15.0 vs. 7.2 months). Another 
retrospective study measured the SVZ dose-volume parameters and found a correlation with the 
survival outcome of 40 patients with GBM [131]. Multivariate Cox regression analyses for important 
prognostic factors (age, KPS, surgery type) revealed that higher ipsilateral SVZ irradiation doses were not 
found to be independent predictors for PFS but for OS. Furthermore, higher irradiation of the 
contralateral SVZ (>57.9 Gy) was associated with worse prognosis. Likewise, it has also been shown 
by another study that the SVZ involvement during radiotherapy is an independent predictive factor for 
shorter PFS and OS [123]. More recently, the UCLA group confirmed their previous data about the 
impact of SVZ irradiations on PFS and OS on a larger cohort of 173 patients by Cox regression 
analyses including five covariates (ipsilateral and contralateral SVZ doses, clinical target dose, age and 
extent of resection) [132]. Again, a significant correlation was found between high ipsilateral SVZ 
irradiation and improved survival, both for PFS and OS. Multivariate analysis only confirmed this 
advantage for PFS. Last but not least, a recent retrospective study confirmed these trends and specified 
that patients with GBM are more likely to benefit from SVZ irradiation when gross total resection was 
performed [133]. In this case, PFS was significantly higher in patients receiving ipsilateral SVZ doses 
of 40 Gy or above (15.1 vs. 10.3 months). Interestingly, OS was also significantly improved in patients 
receiving ipsilateral SVZ doses of 40 Gy or above (17.5 vs. 15.6 months). Such benefits could not be 




observed in patients treated with biopsy and subtotal surgery. Obviously, those retrospective studies do 
not seem to be sufficiently robust to provide assurance that there is a consistent role of the SVZ contact 
in the GBM tumorigenicity. 
5. Conclusions 
While it is apparent that targeting GICs and neurogenic niches, given their particular architectures, 
should be seen as a great opportunity to improve the survival of GBM patients, critical data are 
nowadays still lacking. Indeed, further studies inquiring the origin(s) and the exact definition of GICs 
as well as robust prospective clinical trials are mandatory. We are convinced that a better understanding 
of the relationship between GICs and the so called neurogenic niches will provide new insights in 
order to improve or to set up new therapeutic strategies for highly malignant brain tumors. Indeed, 
even if the percentage of patients who survive two years from diagnosis of GBM has more than tripled 
in the last five years, largely because of the use of temozolomide plus radiation in addition to progress 
made with bevacizumab, research on treatment options for GBM is way more exciting now than ever 
before. Nowadays, the development of state-of-the-art neuroimaging techniques for improved surgical 
resections, vaccines and therapies aiming molecular targets as well as signaling pathways are bit by bit 
bending the tail end of the curve and raise great hope of making major improvements for GBM patients. 
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